Bioresorbable scaffolds in the treatment of coronary artery disease

50Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

Abstract

Drug-eluting stents have reduced the risk of in-stent restenosis and have broadened the application in percutaneous coronary intervention in coronary artery disease. However, the concept of using a permanent metallic endovascular device to restore the patency of a stenotic artery has inherited pitfalls, namely the presence of a foreign body within the artery causing vascular inflammation, late complications such as restenosis and stent thrombosis, and impeding the restoration of the physiologic function of the stented segment. Bioresorbable scaffolds (BRS) were introduced to potentially overcome these limitations, as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. Currently, several BRSs are available, undergoing evaluation either in clinical trials or in preclinical settings. The aim of this review is to present the new developments in BRS technology, describe the mechanisms involved in the resorption process, and discuss the potential future prospects of this innovative therapy. © 2013 Zhang et al, publisher and licensee Dove Medical Press Ltd.

Cite

CITATION STYLE

APA

Zhang, Y., Bourantas, C. V., Farooq, V., Muramatsu, T., Diletti, R., Onuma, Y., … Serruys, P. W. (2013, March 11). Bioresorbable scaffolds in the treatment of coronary artery disease. Medical Devices: Evidence and Research. https://doi.org/10.2147/MDER.S22547

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free